171 related articles for article (PubMed ID: 22609836)
1. Comparison of the effects of DC031050, a class III antiarrhythmic agent, on hERG channel and three neuronal potassium channels.
Li P; Sun HF; Zhou PZ; Ma CY; Hu GY; Jiang HL; Li M; Liu H; Gao ZB
Acta Pharmacol Sin; 2012 Jun; 33(6):728-36. PubMed ID: 22609836
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of the hERG potassium channel is modulated by extracellular but not intracellular acidosis.
DU CY; El Harchi A; Zhang YH; Orchard CH; Hancox JC
J Cardiovasc Electrophysiol; 2011 Oct; 22(10):1163-70. PubMed ID: 21489024
[TBL] [Abstract][Full Text] [Related]
3. Molecular determinants of dofetilide block of HERG K+ channels.
Ficker E; Jarolimek W; Kiehn J; Baumann A; Brown AM
Circ Res; 1998 Feb; 82(3):386-95. PubMed ID: 9486667
[TBL] [Abstract][Full Text] [Related]
4. Effects of the class III antiarrhythmic agent dofetilide (UK-68,798) on L-type calcium current from rabbit ventricular myocytes.
Paul AA; Leishman DJ; Witchel HJ; Hancox JC
J Pharm Pharmacol; 2001 Dec; 53(12):1671-8. PubMed ID: 11804397
[TBL] [Abstract][Full Text] [Related]
5. Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels.
Dong DL; Li Z; Wang HZ; Du ZM; Song WH; Yang BF
Basic Clin Pharmacol Toxicol; 2004 May; 94(5):209-12. PubMed ID: 15125690
[TBL] [Abstract][Full Text] [Related]
6. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.
Rampe D; Roy ML; Dennis A; Brown AM
FEBS Lett; 1997 Nov; 417(1):28-32. PubMed ID: 9395068
[TBL] [Abstract][Full Text] [Related]
7. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide.
Kiehn J; Lacerda AE; Wible B; Brown AM
Circulation; 1996 Nov; 94(10):2572-9. PubMed ID: 8921803
[TBL] [Abstract][Full Text] [Related]
8. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
[TBL] [Abstract][Full Text] [Related]
9. Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.
Ficker E; Jarolimek W; Brown AM
Mol Pharmacol; 2001 Dec; 60(6):1343-8. PubMed ID: 11723241
[TBL] [Abstract][Full Text] [Related]
10. The Susceptibilities of Human Ether-à-Go-Go-Related Gene Channel with the G487R Mutation to Arrhythmogenic Factors.
Hisajima N; Hata Y; Kinoshita K; Fukushima T; Nishida N; Kano M; Tabata T
Biol Pharm Bull; 2015; 38(5):781-4. PubMed ID: 25947924
[TBL] [Abstract][Full Text] [Related]
11. Open channel block by KCB-328 [1-(2-amino-4-methanesulfonamidophenoxy)-2-[N-(3,4-dimethoxyphenethyl)-N-methylamino]ethane hydrochloride] of the heterologously expressed human ether-a-go-go-related gene K+ channels.
Park JB; Choe H; Lee YK; Ha KC; Rhee KS; Ko JK; Joo CU; Chae SW; Kwak YG
J Pharmacol Exp Ther; 2002 Jul; 302(1):314-9. PubMed ID: 12065732
[TBL] [Abstract][Full Text] [Related]
12. Dofetilide block involves interactions with open and inactivated states of HERG channels.
Weerapura M; Hébert TE; Nattel S
Pflugers Arch; 2002 Feb; 443(4):520-31. PubMed ID: 11907818
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue.
Varkevisser R; Houtman MJ; Linder T; de Git KC; Beekman HD; Tidwell RR; Ijzerman AP; Stary-Weinzinger A; Vos MA; van der Heyden MA
Br J Pharmacol; 2013 Jul; 169(6):1322-34. PubMed ID: 23586323
[TBL] [Abstract][Full Text] [Related]
14. Stereoselective interactions of the enantiomers of chromanol 293B with human voltage-gated potassium channels.
Yang IC; Scherz MW; Bahinski A; Bennett PB; Murray KT
J Pharmacol Exp Ther; 2000 Sep; 294(3):955-62. PubMed ID: 10945846
[TBL] [Abstract][Full Text] [Related]
15. Vascular effects of class-III antiarrhythmic drugs: chromanol 293B, but not dofetilide blocks the smooth muscle delayed rectifier K+ channel.
Karle CA; Bauer A; Weretka S; Zitron E; Abushi A; Kreye VA; Schoels W
Basic Res Cardiol; 2002 Jan; 97(1):17-25. PubMed ID: 11998973
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide.
Paul AA; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2001 Feb; 280(5):1243-50. PubMed ID: 11162661
[TBL] [Abstract][Full Text] [Related]
17. A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?
Weerapura M; Nattel S; Chartier D; Caballero R; Hébert TE
J Physiol; 2002 Apr; 540(Pt 1):15-27. PubMed ID: 11927665
[TBL] [Abstract][Full Text] [Related]
18. Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides.
Spector PS; Curran ME; Keating MT; Sanguinetti MC
Circ Res; 1996 Mar; 78(3):499-503. PubMed ID: 8593709
[TBL] [Abstract][Full Text] [Related]
19. Differential recovery of action potential duration and HERG currents from the effects of two methanesulfonamide class III antiarrhythmic agents, KCB-328 and dofetilide.
Lee K; Park JB; Jeon BH; Kim KJ; Ryu PD; Kwon LS; Kim HY
J Cardiovasc Pharmacol; 2003 Nov; 42(5):648-55. PubMed ID: 14576514
[TBL] [Abstract][Full Text] [Related]
20. High affinity open channel block by dofetilide of HERG expressed in a human cell line.
Snyders DJ; Chaudhary A
Mol Pharmacol; 1996 Jun; 49(6):949-55. PubMed ID: 8649354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
